Clinical trials: 2019-nCoV Pneumonia
COVID-19, Pneumonia, Viral
SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19
This protocol provides access to eculizumab treatment for participants with severe COVID-19.
- Conditions
- COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT04355494
- Testing
- eculizumab
- Where
- 12 sites in United States, France
- Sponsor
- Alexion Pharmaceuticals, Inc.
Coronavirus, Corona Virus Infection
PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs
PHENOTYPE is an investigator-led, observational cohort study which aims to explore the long-term outcomes of patients with COVID-19 infection and to identify potential risk factors and biomarkers that can prognosticate disease…
- Conditions
- Coronavirus, Corona Virus Infection, COVID-19, 2019nCoV
- Trial name
- PHENOTYPE (NCT04459351)
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
COVID-19, Corona Virus Infection
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV-2, 2019-nCoV
- Trial name
- NCT04334967
- Testing
- Hydroxychloroquine, Vitamin C
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Providence Health & Services
Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2)
A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- CONTACT (NCT04611230)
- Where
- United States
- Volunteers
- 1,007 people
- Sponsor
- AbbVie
COVID-19, Coronavirus 2019
Genetics of COVID-19 Susceptibility and Manifestations
Background: Coronavirus 2019 (COVID-19, or SARS-CoV-2) is a serious public health problem, and genetics may play a role in how serious the illness becomes in certain people.
- Trial name
- NCT04371432
- Where
- United States
- Volunteers
- 721 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Coronavirus Infectious Disease 2019 (COVID-19)
COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)
This study is to establish an accurate, robust and easily scalable COVID-19 viral nucleic acid analysis platform from, but not limited to, saliva to help enable and support contact tracing in the canton of Baselland/ Switzerland.
- Trial name
- NCT04625257
- Testing
- Saliva based assay: crude RNA extraction, Validation of the NGS method, Validation of the LAMP assays
- Where
- Switzerland
- Volunteers
- 1,600 people
- Sponsor
- University Hospital, Basel, Switzerland
COVID-19
Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection
The study purpose was to assess the outcomes of therapy with olokizumab within complex therapy of Coronavirus disease 2019 (COVID-19) in hospitalised patients in real clinical practice setting.
- Trial name
- ROCOVI (NCT05196477)
- Testing
- Olokizumab, Standard therapy
- Where
- 6 sites in Russia
- Volunteers
- 3,087 people
- Sponsor
- R-Pharm
COVID-19
SCB-2019 as COVID-19 Vaccine
This is a randomized, double blind, placebo controlled, first-in-human (FIH) study to assess safety, reactogenicity, and immunogenicity of SCB-2019 at multiple dose levels, administered as 2 injections IM in healthy subjects.
- Trial name
- NCT04405908
- Testing
- SCB-2019, SCB-2019 with AS03 adjuvant, SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
- Where
- Australia
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Acute Pancreatitis, 2019 Novel Coronavirus Infection
Study and Analysis of Acute Pancreatitis Complicated With COVID-19
The goal of this observational study was to explore the complex relationship between changes in the intestinal microbiome and serum metabolites in patients with novel coronavirus infection and acute pancreatitis.
- Trial name
- NCT05722678
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yuansong Sun
Post-COVID-19
Sleep Characteristics in Post-COVID-19 Patients
After acute infection, patients with coronavirus disease 2019 (COVID-19) often suffer from persisting symptoms for more than 3 months (post COVID-19).
- Trial name
- NCT05124548
- Testing
- Sleep diagnostics
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Schön Klinik Berchtesgadener Land
2019 Novel Coronavirus Infection
Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff
The investigators plan to carry out an experimental study on the preventive effect of recombinant human interferon alpha nasal drops on the infection of 2019 new coronavirus in medical staff.
- Trial name
- NCT04320238
- Testing
- recombinant human interferon Alpha-1b, thymosin alpha 1
- Where
- China
- Volunteers
- 2,944 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Coronavirus Disease 2019
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
This is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04672564
- Testing
- Carrimycin
- Where
- 17 sites in United States, Argentina and 4 more
- Volunteers
- 93 people
- Sponsor
- Shenyang Tonglian Group CO., Ltd
Covid19, SARS (Severe Acute Respiratory Syndrome)
Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Coronavirus Disease 2019 (COVID-19) (previously called 2019-nCOV acute respiratory disease) is caused by SARS-CoV-2, a positive-sense single-stranded RNA virus of the coronavirus family.
- Trial name
- NCT04590274
- Testing
- Hydroxychloroquine, Vitamins and Minerals, Azithromycin
- Volunteers
- healthy volunteers welcome
- Sponsor
- International Brain Research Foundation
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, COVID-19 Pandemic
- Trial name
- NCT05364268
- Testing
- Diagnostic Test: Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 514 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
Healthy Participants
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
- Trial name
- NCT07093580
- Testing
- S-892216-LAI
- Where
- 3 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Shionogi
Covid19
Risk Factors Worsening COVID19 for Out-patient With Home Monitoring
The main objective of the COVIDADOMEVA study is to identify the risk factors aggravating the COVID-19 (risk or protective factors), in out-patients suspected of being infected with precocious home monitoring.
- Trial name
- COVIDADOMEVA (NCT04380662)
- Testing
- Risk factors
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Grenoble
2019 Novel Coronavirus Infection, COVID-19 Virus Infection
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
This trial will study the use of USB002 given as an intravenous infusion in patients with respiratory distress due to infection with COVID-19.
- Conditions
- 2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection
- Trial name
- NCT04778059
- Testing
- USB002
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- US Biotest, Inc.
COVID-19, 2019 Novel Coronavirus Infection
Evaluating Clinical Parameters of COVID-19 in Pregnancy
Coronavirus infection, also known as COVID-19, has become a global pandemic with over 3 million cases and 250,000 deaths worldwide.
- Conditions
- COVID-19, 2019 Novel Coronavirus Infection, COVID-19 Infection
- Trial name
- COpregVID (NCT04470583)
- Where
- 2 sites in United Kingdom
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
COVID-19, SARS-CoV-2
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
- Trial name
- NCT04472494
- Testing
- Abatacept
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
SARS-CoV-2
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to <6 years, when…
- Trial name
- NCT05436834
- Testing
- mRNA-1273.214, mRNA-1273.815
- Where
- 74 sites in United States, Argentina and 5 more
- Volunteers
- 1,807 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.